New insight into therapies targeting angiogenesis in hepatocellular carcinoma

Monica Mossenta, Davide Busato, Lorena Baboci, Federica Di Cintio, Giuseppe Toffoli, Michele Dal Bo

Research output: Contribution to journalReview article

Abstract

Hepatocellular carcinoma (HCC) is a malignancy characterized by neoangiogenesis that is determined by an augmented production of proangiogenesis factors by tumor and adjacent cells. This unbalanced angiogenesis process is a key feature of HCC carcinogenesis and progression. Proangiogenic factors also have a relevant role in the generation and maintenance of an immunosuppressive tumor microenvironment. Several therapeutic options for HCC treatment are based on the inhibition of angiogenesis, both in the early/intermediate stages of the disease and in the late stages of the disease. Conventional treatment options employing antiangiogenic approaches provide for the starving of tumors of their blood supply to avoid the refueling of oxygen and nutrients. An emerging alternative point of view is the normalization of vasculature leading to enhance tumor perfusion and oxygenation, potentially capable, when proposed in combination with other treatments, to improve delivery and efficacy of other therapies, including immunotherapy with checkpoint inhibitors. The introduction of novel biomarkers can be useful for the definition of the most appropriate dose and scheduling for these combination treatment approaches. The present review provides a wide description of the pharmaceutical compounds with an antiangiogenic effect proposed for HCC treatment and investigated in clinical trials, including antibodies and small-molecule kinase inhibitors.

Original languageEnglish
Article number1086
Number of pages20
JournalCancers
Volume11
Issue number8
DOIs
Publication statusPublished - Aug 2019

Keywords

  • Angiogenesis
  • HCC
  • Immunotherapy
  • Small-molecule kinase inhibitors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'New insight into therapies targeting angiogenesis in hepatocellular carcinoma'. Together they form a unique fingerprint.

  • Cite this